NEUMOUS is a startup founded by faculty members of Gachon University, developing ultrasound-cavitation medical devices that regulate the blood-brain barrier (BBB).
The BBB is a critical defense mechanism that protects the brain from external substances. However, it also blocks the delivery of brain disease therapeutics, limiting their effectiveness. Currently, about 95% of brain disease-related drugs cannot effectively penetrate the BBB, resulting in suboptimal therapeutic outcomes and challenges in clinical success.
NEUMOUS's core technology, NMS-01, uses ultrasound to temporarily open the BBB, enhancing drug permeability and enabling effective delivery of therapeutics to brain-damaged areas. Through collaboration with global pharmaceutical companies, NEUMOUS aims to drive innovation in brain disease treatment development and clinical trials.
